The Latest Breaking News from FSE

Rangers Europa League final latest as club plan UEFA report over 'issues' faced in Seville

Fans were left without water and a severe lack of food at the Europa League Final while many complaints were made about policing procedures outside the ground.

Glasgow Live · May 30, 2022

Rangers team up with Eintracht Frankfurt and supporters group following Europa League final fan complaints in Seville

RANGERS have issued a joint statement with Eintracht Frankfurt following the treatment of their supporters in Seville for the Europa League final.

The National (Scotland) · May 30, 2022

French ministry accused of ‘prejudice against Liverpool fans’ following Champions League final police tactics

The scenes outside the Stade de France left some supporters with genuine tickets sprayed by police before kick-off and claiming attacks from locals afterwards

The Independent UK · May 29, 2022

Rangers raise 'major concerns' over treatment of fans at Europa League Final

The club released a statement this afternoon following last week's Europa League final defeat at the hands of Eintracht Frankfurt.

Daily Record · May 24, 2022

Influential supporters' body FSE urges Rangers fans to have their say on Europa League Final issues

Many who attended have complained about a lack of drinking water in scorching temperatures.

Daily Record · May 23, 2022

Future of European Super League discussed at key meeting

The private meeting, to discuss the future of football on the continent, was set to involve a representative of Andrea Agnelli’s office

The Independent UK · Apr 28, 2022

Uefa backs petition calling for the principles of sporting merit to be protected

Fans’ representatives met with the governing body a year on from the Super League’s collapse

The Independent UK · Apr 21, 2022

Novamind To Host MindMed Phase IIb Trial For LSD Based Drug For Anxiety Treatment

Novamind Inc. (OTCQB:NVMDF) (CSE:NM) (FSE:HN2) has been selected by Mind Medicine, Inc. (NASDAQ:MNMD) (NEO:MMED) to host a Phase IIb randomized clinical trial investigating lysergic acid diethylamide (LSD) for generalized anxiety disorder in adults.

Benzinga · Mar 16, 2022

Novamind Stock Slightly Up On Grants Restricted Share Units

Novamind Inc. (OTCQB:NVMDF)(CSE:NM)(FSE:HN2) a mental health company specialized in psychedelic medicine, has granted an aggregate of 325,000 restricted share units effective March 11, 2022, to certain executives and employees of the company pursuant to its restricted share unit plan. The RSUs will vest in 25% intervals, every 6 months from…

Benzinga · Mar 11, 2022

Novamind To Conduct Phase II Psilocybin Trial For Major Depressive Disorder

Novamind Inc. (OTCQB:NVMDF) (CSE:NM)(FSE:HN2) will conduct a phase II clinical trial investigating psilocybin for major depressive disorder sponsored by the Usona Institute. The company completed first patient randomization at its Draper, Utah research site.

Benzinga · Mar 9, 2022